Medica Jadertina, Vol. 43 No. 1-2, 2013.
Stručni rad
The effect of intravitreal bevacizumab on visual acuity in exudative form of age-related macular degeneration treatments
Jasna Muhović-Bejtić
; Opća bolnica "Prim.dr. Abdulah Nakaš", Odsjek za oftalmologiju, Sarajevo, Bosna i Hercegovina
Sažetak
The aim of the research is to determine whether intravitreal bevacizumab improves the visual acuity significance in treatment of patients with exudative form of age-related macular degeneration.
Patients and methods: This study included 45 patients, 75 eyes with senile degeneration of the macula lutea, who were treated in Prim. dr. Abdulah Nakas General Hospital during the period from November
2007 - November 2010. The criteria for inclusion of patients in the study were that they had clinical signs of age-related degeneration of macula lutea with diagnostic methods verifying the changes in the retina, and aged between 55 and 75 years.
Result: The average age of patients treated with bevacizumab was 71.27 years (71 years, 3 months and 7 days). The study included 28 female patients and 17 male patients. There was a statistically significant difference (p <0.05) in visual acuity between any measurement period. The smallest difference was between
4 and 6 months but still statistically significant. If we analyze the trend line, we can conclude that it is logarithmic, which shows that there is a trend of improvement.
Conclusion: The results of the application of bevacizumab intravitreally in age-related degeneration of the macula lutea showed that intravitreal bevacizumab for exudative form of age-related macular degeneration improved the visual function of patients, which significantly affected the extension of their active life expectancy.
Ključne riječi
bevacizumab; visual acuity; macular degeneration
Hrčak ID:
100569
URI
Datum izdavanja:
23.4.2013.
Posjeta: 1.336 *